Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: A 12-month, randomized, placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2644-2647

  Franco, Celina ^a   Andersson, Björn ^a   Lönn, Lars ^a   Bengtsson, Bengt Åke ^a   Svensson, Johan ^a   Johannsson, Gudmundur ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; GROWTH HORMONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLACEBO; SOMATOMEDIN; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL OBESITY; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INFLAMMATION; INTRAABDOMINAL FAT; PARALLEL DESIGN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION;

EID: 34447126377     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0068     Document Type: Article

References (20)

1. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS 1997 Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 272:E1108-E1116
2. Blake GJ, Ridker PM 2002 Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283-294
3. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y, Nagai R 2006 C-reactive protein induces VCAM-1 gene expression through NF-κB activation in vascular endothelial cells. Atherosclerosis 185:39-46
4. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I 2002 Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106:1439-1441
5. Matsumoto K, Sera Y, Abe Y, Tominaga T, Horikami K, Hirao K, Ueki Y, Miyake S 2002 High serum concentrations of soluble E-selectin correlate with obesity but not fat distribution in patients with type 2 diabetes mellitus. Metabolism 51:932-934
6. Bengtsson BA 1993 The consequences of growth hormone deficiency in adults. Acta Endocrinol (Copenh) 128(Suppl 2):2-5
7. Bengtsson BA, Rosén T, Johansson J-O, Johannsson G, Oscarsson J, Landin-Wilhelmsen K 1995 Cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 2(Suppl B):29-35
8. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111-122
9. Falk E, Shah PK, Fuster V 1995 Coronary plaque disruption. Circulation 92:657-671
10. Randeva HS, Lewandowski KC, Komorowski J, Murray RD, O'Callaghan CJ, Hillhouse EW, Stepien H, Shalet SM 2004 Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation 109:2405-2410
11. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G 2005 Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 90:1466-1474
12. Sesmilo G, Miller KK, Hayden D, Klibanski A 2001 Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86:5774-5781
13. van Buul-Offers SC, Kooijman R 1998 The role of growth hormone and insulin-like growth factors in the immune system. Cell Mol Life Sci 54:1083-1094
14. Hansen TK, Fisker S, Dall R, Ledet T, Jorgensen JO, Rasmussen LM 2004 Growth hormone increases vascular cell adhesion molecule 1 expression: in vivo and in vitro evidence. J Clin Endocrinol Metab 89:909-916
15. Leung KC, Johannsson G, Leong GM, Ho KK 2004 Estrogen regulation of growth hormone action. Endocr Rev 25:693-721
16. Grundy SM 2002 Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105:2696-2698
17. Heinrich PC, Castell JV, Andus T 1990 Interleukin-6 and the acute phase response. Biochem J 265:621-636
18. Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P 2006 Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154:537-543
19. Gomez JM, Sahun M, Vila R, Domenech P, Catalina P, Soler J, Badimon L 2006 Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 64:632-639
20. Colao A, Di Somma C, Rota F, Pivonello R, Savanelli MC, Spiezia S, Lombardi G 2005 Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90:2056-2062